This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moore, T. J. Articles by Williams, G. H. Search for Related Content PubMed PubMed Citation Articles by Moore, T. J. Articles by Williams, G. H.

Hypertension, Vol 3, 168-173, Copyright © 1981 by American Heart Association

ARTICLES

Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension

TJ Moore, FR Crantz, NK Hollenberg, RJ Koletsky, MS Leboff, SL Swartz, L Levine, S Podolsky, RG Dluhy and GH Williams

To determine whether prostaglandins contribute to the depressor response to the converting enzyme inhibitor, captopril, we measured the plasma prostaglandin levels by radioimmunoassy before and after captopril administration, and then examined the effect of prostaglandin synthetase inhibition on captopril's antihypertensive effect. When a single oral captopril dose (25-100 mg) was given to 31 sodium- restricted patients with essential hypertension, the levels of the stable transformation product of prostacyclin remained unmeasurable and that of thromboxane A2 did not change, while the metabolite of PGE2 (PGE-M) increased by 53% (34 +/- 4pg/ml pre-captopril, 52 +/- 5 pg/ml after; p less than 0.001). As expected, blood pressure (BP) and angiotension II (AII levels fell, and kinin levels rose (all changes p less than 0.001). We then blocked prostaglandin synthesis in 18 of these subjects for 24 hours with either indomethacin (n = 10) or aspirin (n = 8) before repeating the captopril dose, to assess the importance of these PGE-M increments. The PGE-M responses to captopril were effectively blocked in nine of 10 subjects receiving indomethacin and four of eight receiving aspirin. In these 13 patients, the depressor response to captopril was significantly blunted (-20 +/- 3mm Hg pre-synthetase inhibition vs - 13 +/- 2 mm Hg post; p less than 0.05). When these agents did not block the PGE-M response to captopril, the BP response was also unchanged (-15 +/- 4mm Hg pre, -18 +/- 5mm Hg post). Neither indomethacin nor aspirin changed the AII or kinin responses to captopril. We conclude that the prostaglandins may be important mediators of captopril's antihypertensive effect in the sodium-restricted state.

This article has been cited by other articles:

				J. Lindenfeld, A. D. Robertson, B. D. Lowes, M. R. Bristow, and for the MOCHA Investigators Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1950 - 1956. [Abstract] [Full Text] [PDF]

				P. R. Conlin, T. J. Moore, S. L. Swartz, E. Barr, L. Gazdick, C. Fletcher, P. DeLucca, and L. Demopoulos Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients Hypertension, September 1, 2000; 36(3): 461 - 465. [Abstract] [Full Text] [PDF]

				T. Stys, W. E. Lawson, G. C. Smaldone, and A. Stys Does Aspirin Attenuate the Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Heart Failure? Arch Intern Med, May 22, 2000; 160(10): 1409 - 1413. [Abstract] [Full Text] [PDF]

				F. H. WAPSTRA, G. NAVIS, P. E. DE JONG, and D. DE ZEEUW Chronic Angiotensin II Infusion But Not Bradykinin Blockade Abolishes the Antiproteinuric Response to Angiotensin-Converting Enzyme Inhibition in Established Adriamycin Nephrosis J. Am. Soc. Nephrol., March 1, 2000; 11(3): 490 - 496. [Abstract] [Full Text] [PDF]

				J. Leor, H. Reicher-Reiss, U. Goldbourt, V. Boyko, S. Gottlieb, A. Battler, and S. Behar Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: A cohort study of 11,575 patients with coronary artery disease J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1920 - 1925. [Abstract] [Full Text] [PDF]

				N. J. Brown and D. E. Vaughan Angiotensin-Converting Enzyme Inhibitors Circulation, April 14, 1998; 97(14): 1411 - 1420. [Abstract] [Full Text] [PDF]

				M. Bramucci, A. Miano, A. Gobbetti, M. Zerani, L. Quassinti, E. Maccari, O. Murri, and D. Amici Different modulation of steroidogenesis and prostaglandin production in frog ovary in vitro by ACE and ANG II Am J Physiol Regulatory Integrative Comp Physiol, December 1, 1997; 273(6): R2089 - R2096. [Abstract] [Full Text] [PDF]

				V. Cachofeiro, R. Maeso, E. Rodrigo, J. Navarro, L. M. Ruilope, and V. Lahera Nitric Oxide and Prostaglandins in the Prolonged Effects of Losartan and Ramipril in Hypertension Hypertension, August 1, 1995; 26(2): 236 - 243. [Abstract] [Full Text]

				M. C. Houston, M. Weir, J. Gray, D. Ginsberg, C. Szeto, P. M. Kaihlenen, D. Sugimoto, M. Runde, and M. Lefkowitz The Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressures of Patients With Hypertension Controlled by Verapamil Arch Intern Med, May 22, 1995; 155(10): 1049 - 1054. [Abstract] [PDF]

				S. Chrysant Bilateral Renal Artery Stenosis-Reply Arch Intern Med, November 1, 1984; 144(11): 2282 - 2282. [Abstract] [PDF]